Answers are grounded in this paper and cite their sources.
Introduction and Objective: Dorzagliatin, a novel class of glucokinase activator, enhances glycemic control in T2D patients by targeting pancreatic, intestinal, and hepatic GK. This subgroup analysis evaluates dorzagliatin’s efficacy in T2D patients based on different TIR levels. Methods: This ongoing prospective cohort study launched in April 2024 in Tianjin, China, enrolled T2D patients who were initiated on dorzagliatin in a real-world setting. For this subgroup analysis, patients were grouped by baseline TIR levels: TIR≤50%, 50%<TIR≤70%, TIR>70%. Endpoints included HbA1c and CGM metrics. Continuous variables were analyzed using paired t-tests or Wilcoxon signed-rank tests. Results: As of February 1, 2026, a total of 255 participants (145 males, 110 females; mean age 52.7±11.5y; diabetes duration 9.9±7.3y; BMI 27.3±4.2kg/m2) had baseline CGM data, with 34 (13.33%) in TIR≤50%, 76 (29.80%) in 50%<TIR≤70%, 145 (56.87%) in TIR>70% group. Among these patients, 64.26% (151/235) received more than 3 types of antidiabetic medications and 37.45% (88/235) were on insulin therapy at baseline. After six months, HbA1c significantly decreased from 9.3±1.7% to 8.0±1.4% in TIR≤50%, 8.2±1.0% to 7.4±1.0% in 50%<TIR≤70%, and 8.5±1.4% to 7.5±1.2% in TIR>70% group (all P<0.01). TIR improved from 33.3±12.0% to 61.5±20.0% (P<0.01) in TIR≤50% group and from 60.0±5.2% to 67.9±19.2% in 50%<TIR≤70% group (P=0.02), with no significant increase in TBR. In TIR>70% group, TIR remained stable at 80.1±14.1%. Conclusion: Dorzagliatin demonstrates promising efficacy in glycemic control in real-world T2D patients characterized by a long disease duration and a high prevalence of combination therapy with multiple antidiabetic agents including insulin, even in cases with severely compromised baseline TIR.
No takes yet. Share an insight, caveat, or question.
HAN et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: